0001029142FALSE00010291422025-02-032025-02-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 8-K
______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2025
    
______________________________________________________
Dynavax Technologies Corporation
(Exact name of Registrant as Specified in Its Charter)
______________________________________________________
Delaware001-3420733-0728374
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

2100 Powell Street, Suite 720
Emeryville, CA
94608
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 848-5100
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par valueDVAXNasdaq Global Select Market
Preferred Share Purchase Rights
N/A
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 1.01 Entry into a Material Definitive Agreement.

On February 10, 2025 (the “Effective Date”), Dynavax Technologies Corporation (the “Company”) entered into an agreement (the “Supply Agreement”) with West Pharmaceutical Services, Inc. (“West”), for the manufacture and supply of syringe stoppers (the “Product”) for the Company’s HEPLISAV-B® vaccine. The Supply Agreement replaces entirely the Company’s prior Supply Agreement dated July 27, 2016 with West, which was previously filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Under the Supply Agreement, the Company is obligated to purchase certain volumes of the Product from West, subject to certain adjustments. Pricing for the Product is based on the volume purchased in a calendar year. Such pricing is subject to change during the term of the Supply Agreement in line with a specified price index.
The term of the Supply Agreement is four years from the Effective Date, subject to certain extensions.
Each party has the right to terminate the Supply Agreement prior to its expiration (i) for uncured material breach, and (ii) in the event the other party becomes insolvent, bankrupt, makes an assignment for the benefit of creditors, or otherwise becomes subject to a plan of reorganization.
The foregoing summary description of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Supply Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 13, 2025, the Board of Directors of the Company appointed Kelly MacDonald, the Company’s Chief Financial Officer and principal financial officer, as the Company’s principal accounting officer, effective immediately.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dynavax Technologies Corporation
Date:
February 14, 2025
By: /s/ RYAN SPENCER
Ryan Spencer
Chief Executive Officer

v3.25.0.1
Document And Entity Information
Feb. 03, 2025
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 10, 2025
Entity Registrant Name Dynavax Technologies Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 001-34207
Entity Tax Identification Number 33-0728374
Entity Address, Address Line One 2100 Powell Street
Entity Address, Address Line Two Suite 720
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 848-5100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol DVAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001029142
Amendment Flag false
Grafico Azioni Dynavax Technologies (NASDAQ:DVAX)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Dynavax Technologies
Grafico Azioni Dynavax Technologies (NASDAQ:DVAX)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Dynavax Technologies